Guideline-Directed Medical Therapy for Heart Failure

Heart Failure with Reduced Ejection Fraction (HFrEF) Management

• The American College of Cardiology recommends the use of Renin-Angiotensin System Inhibitors, such as ACE inhibitors, ARBs, or preferably ARNI (sacubitril/valsartan), to reduce mortality by 5-16% for ACEi/ARBs and at least 20% for ARNI in patients with HFrEF 1, 2
• The European Society of Cardiology suggests the use of Beta-Blockers, specifically carvedilol, metoprolol succinate, or bisoprolol, to provide at least 20% reduction in mortality risk in patients with HFrEF 2
• The American College of Cardiology recommends the use of Mineralocorticoid Receptor Antagonists (MRAs), such as spironolactone or eplerenone, to provide at least 20% reduction in mortality risk in patients with HFrEF 2
• The American College of Cardiology recommends the use of SGLT2 Inhibitors, such as dapagliflozin or empagliflozin, as the newest class added to HFrEF therapy with significant mortality benefits 3, 4
• Combined quadruple therapy reduces mortality risk by approximately 73% over 2 years compared to no treatment in patients with HFrEF 1, 5
• Transitioning a patient from traditional dual therapy (ACEi and beta-blocker) to quadruple therapy can extend life expectancy by approximately 6 years in patients with HFrEF 5, 6

Heart Failure with Preserved Ejection Fraction (HFpEF) Management

• The American College of Cardiology recommends the use of SGLT2 Inhibitors as the strongest recommendation (Class 2a) for HFpEF based on DELIVER and EMPEROR-PRESERVED trials showing reduction in HF hospitalizations and cardiovascular death 7, 4
• The American College of Cardiology suggests the use of Mineralocorticoid Receptor Antagonists with a weaker recommendation (Class 2b) based on TOPCAT trial data showing benefit in reducing HF hospitalizations in patients with HFpEF 7, 4
• The American College of Cardiology recommends hypertension control as a cornerstone of HFpEF management (Class I recommendation) 3, 7
• The American College of Cardiology suggests the treatment of atrial fibrillation for symptom management (Class 2a recommendation) in patients with HFpEF 7

Key Differences in Guideline-Directed Medical Therapy Approach

• The American College of Cardiology notes that HFrEF has a strong mortality benefit with all four medication classes (Class I recommendations) 1, 4
• The American College of Cardiology notes that HFpEF has primarily reduction in hospitalizations rather than mortality, with SGLT2i having the strongest evidence (Class 2a) 7, 4
• The American College of Cardiology recommends a phenotype-directed approach focusing on comorbidity management (hypertension, diabetes, obesity, atrial fibrillation) alongside specific HF therapies in patients with HFpEF 7

Special Considerations

• Patients with previous HFrEF whose EF improves to >40% should continue their HFrEF treatment regimen 3, 4
• Discontinuation of HFrEF medications after EF improvement may lead to clinical deterioration 4
• Adverse events are common in heart failure patients, but most are not attributable to GDMT medications and should not prevent appropriate therapy initiation 8

Management of Pulmonary Hypertension in HFrEF

Optimizing GDMT for HFrEF with Pulmonary Hypertension

• The American College of Cardiology recommends optimizing the existing GDMT regimen to target doses for patients with HFrEF and severe pulmonary hypertension, as this is the most effective approach for treating pulmonary hypertension secondary to left heart disease 9, 10
• Optimization of GDMT for HFrEF is the cornerstone of management for pulmonary hypertension in this setting, with a focus on titrating medications to target doses or highest tolerated doses 10
• Titration to target doses is crucial, providing the greatest mortality benefit, with only 1% of patients receiving all medications at target doses 11

Special Considerations

• For patients with low systolic blood pressure (<90 mmHg), the European Society of Cardiology recommends prioritizing medications in a specific order, including SGLT2 inhibitors and MRAs, selective β₁ receptor blockers, and low-dose ACEi/ARB or very low-dose ARNI 12, 13
• For patients with low blood pressure but adequate perfusion, small incremental dose increases with close monitoring are recommended 12, 13
• If beta-blockers are not hemodynamically tolerated, ivabradine may be considered as an alternative for heart rate control 12, 13

Volume Management

• The American Heart Association recommends optimizing diuretic therapy to reduce pulmonary congestion and right ventricular afterload, with consideration of combination diuretic therapy (loop + thiazide) for diuretic resistance 9, 12
• Excessive diuresis should be avoided, as it may worsen hypotension 13

Follow-up and Monitoring

• Early follow-up (within 7-14 days) after medication adjustments is recommended, with monitoring for changes in volume status and blood pressure, renal function and electrolytes, and symptoms of worsening heart failure 9, 13

Advanced Therapies

• If pulmonary hypertension persists despite optimal GDMT, evaluation for advanced HF therapies may be considered, with persistent severe pulmonary hypertension indicating progression to advanced HF requiring specialized interventions 13

Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction

Medication Initiation and Uptitration

• The European Society of Cardiology recommends initiating ACE inhibitors or ARBs and uptitrating to target doses shown effective in trials, as an alternative to ARNI if not tolerated or available 14, 15
• The European Journal of Heart Failure suggests starting mineralocorticoid receptor antagonists (MRAs) at low doses (spironolactone 12.5-25 mg daily or eplerenone 25 mg daily) and uptitrating to target doses, with close monitoring of potassium and creatinine levels 16
• The American College of Cardiology recommends adding loop diuretics only if fluid overload is present, with monitoring of blood pressure, renal function, and electrolytes at 1-2 weeks after each dose increment 14

Forced-Titration Strategy

• The European Journal of Heart Failure recommends starting all four medication classes at low doses simultaneously or in rapid sequence, with uptitration at specific time intervals (typically every 1-2 weeks) until target doses are achieved 17
• The European Journal of Heart Failure suggests that temporary dose reductions should be followed by aggressive attempts to restore target doses, and asymptomatic changes in vital signs and laboratory tests should not prevent uptitration 17

Monitoring and Managing Common Barriers to Uptitration

• The European Heart Journal recommends monitoring blood pressure, renal function, and electrolytes at 1-2 weeks after each dose increment, with more frequent monitoring in patients with renal dysfunction or electrolyte disturbances 14
• The European Journal of Heart Failure suggests that modest increases in creatinine (up to 30% above baseline) are acceptable and should not prompt discontinuation of ACEi/ARB/ARNI, with temporary reduction or hold if substantial renal deterioration occurs 14, 16

Role of Heart Failure Specialty Care

• The Journal of the American College of Cardiology recommends referring newly diagnosed HFrEF patients to HF specialty care to maximize GDMT optimization, with multidisciplinary teams including pharmacists and nurses improving GDMT titration and adherence 18

Guideline-Directed Medical Therapy for Heart Failure

Initial GDMT for Heart Failure with Reduced Ejection Fraction (HFrEF)

• The American Heart Association recommends continuing GDMT in hospitalized patients except when hemodynamically unstable or contraindicated, as stated by the American College of Cardiology 19, 20
• The American College of Cardiology suggests that more frequent monitoring is needed in elderly patients and those with chronic kidney disease during uptitration of GDMT 21
• Initial IV dose of loop diuretics should equal or exceed chronic oral daily dose, and titrate based on urine output and congestion symptoms, as recommended by the American Heart Association 19, 20

Common Pitfalls to Avoid

• The American Heart Association advises against premature discontinuation of GDMT, as temporary symptoms of fatigue and weakness with dose increases usually resolve within days 21
• Overreacting to laboratory changes, such as modest creatinine elevation (up to 30% above baseline), is unacceptable and patients with adequate perfusion can tolerate systolic BP 80-100 mmHg, as stated by the American College of Cardiology 21

GDMT Initiation Strategy for HFrEF

Simultaneous vs Sequential Initiation

• The American College of Cardiology, American Heart Association, and Heart Failure Society of America recommend that all four foundational GDMT medications (ARNI/ACEi/ARB, beta-blocker, MRA, and SGLT2 inhibitor) may be started simultaneously at initial low doses, with no need to achieve target dosing before initiating the next medication 22, 23, 24
• The American College of Cardiology and American Heart Association guidelines state that step 1 medications for HFrEF should be started simultaneously at low initial doses, rather than waiting to achieve target dosing of one medication before initiating the next 22, 23, 24

Special Clinical Scenarios

• The European Society of Cardiology guidelines suggest that if a patient has adequate organ perfusion, do not withhold GDMT, and instead prioritize SGLT2 inhibitors and MRAs first, with minimal BP impact 25
• In hospitalized patients, continue GDMT except when hemodynamically unstable or contraindicated, and in-hospital initiation substantially improves post-discharge medication use compared to deferring initiation to outpatient setting 25, 26

Clinical Context

• Less than one-quarter of eligible patients currently receive all three medications concurrently, and only 1% receive target doses of all medications, representing a massive treatment gap that simultaneous initiation directly addresses 26

Rapid Optimization of Heart Failure Therapy

Key Findings and Guidelines

• The American College of Cardiology recommends initiating all four foundational guideline-directed medical therapy (GDMT) medication classes simultaneously at low doses, rather than sequential initiation, as supported by the STRONG-HF approach 27
• The European Journal of Heart Failure suggests that asymptomatic or mildly symptomatic low blood pressure should not be a reason for GDMT reduction or cessation, with patients with adequate perfusion able to tolerate systolic BP 80-100 mmHg 28

Guideline-Directed Medical Therapy for Heart Failure

Patient Selection and Initiation

• The American College of Cardiology recommends initiating all four foundational GDMT medication classes simultaneously at low doses for patients with heart failure with reduced ejection fraction (HFrEF), which reduces mortality by approximately 73% over 2 years compared to no treatment 29
• The American College of Cardiology suggests that all patients with HFrEF require GDMT regardless of symptom severity, as mortality benefits extend across the entire spectrum 29
• Hospitalized patients should have GDMT initiated after ≥24 hours of stabilization with adequate organ perfusion, according to the American College of Cardiology 30
• For patients with heart failure with preserved ejection fraction (HFpEF), SGLT2 inhibitors are the primary GDMT, with a Class 2a recommendation for reducing HF hospitalizations and cardiovascular death 29

Initiation Strategy and Uptitration

• The American College of Cardiology recommends starting all four medications simultaneously at low doses rather than waiting to achieve target dosing of one before initiating the next 29
• The Journal of the American College of Cardiology suggests a rapid initiation protocol, where all four classes are initiated at low doses after hemodynamic stabilization, with uptitration every 1-2 weeks until target doses are achieved 30
• The American College of Cardiology recommends checking blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment, with more frequent monitoring in elderly patients and those with chronic kidney disease 31

Special Clinical Scenarios

• The American College of Cardiology recommends continuing GDMT except when hemodynamically unstable or contraindicated in hospitalized patients, with initial IV loop diuretic dose equal to or exceeding chronic oral daily dose 29
• For patients with valvular heart disease, the American College of Cardiology suggests optimizing GDMT before any intervention for secondary mitral regurgitation related to LV dysfunction 29

Implementation Strategies

• The Journal of the American College of Cardiology found that nurse-led titration programs reduce all-cause mortality, with an odds ratio of 0.66 (95% CI 0.48-0.92) 32
• The Journal of the American College of Cardiology suggests that pharmacist involvement improves GDMT adherence and dosing, and virtual peer-to-peer consultation increases GDMT initiation rates 32
• The Journal of the American College of Cardiology recommends using digital solutions, such as best practice advisories, electronic health record-based interventions, and telehealth visits, to increase GDMT prescription and improve patient outcomes 33

Guideline-Directed Medical Therapy for Heart Failure

Introduction to GDMT

• The American College of Cardiology recommends that patients with heart failure with reduced ejection fraction (HFrEF) should be initiated on all four medication classes (ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors) simultaneously at low doses and uptitrated to target doses, with ARNI (sacubitril/valsartan) being preferred over ACE inhibitors or ARBs, providing at least 20% reduction in mortality risk 34

Renin-Angiotensin System Inhibitors

• The American College of Cardiology recommends the use of ARNI (sacubitril/valsartan) over ACE inhibitors or ARBs, providing at least 20% reduction in mortality risk, and when switching from ACE inhibitor to ARNI, a strict 36-hour washout period should be observed to avoid angioedema 34

Mineralocorticoid Receptor Antagonists (MRAs)

• The American College of Cardiology recommends the use of MRAs, such as spironolactone or eplerenone, which provide at least 20% reduction in mortality risk, with a 5.7% higher rate of male gynecomastia with spironolactone, which can be avoided with eplerenone use 35

SGLT2 Inhibitors

• The European Society of Cardiology recommends the use of SGLT2 inhibitors, such as dapagliflozin or empagliflozin, which have significant mortality benefits, with no blood pressure, heart rate, or potassium effects, and no dose titration required, with treatment benefits occurring within weeks of initiation, independent of background therapy 36

Critical Implementation Strategy

• The American College of Cardiology recommends starting all four medication classes simultaneously at low initial doses rather than sequential initiation, with less than one-quarter of eligible patients currently receiving all three medications concurrently, and only 1% receiving target doses of all medications 37

Adverse Event Rates

• The American College of Cardiology reports that ACE inhibitors have an 8.9% higher rate of cough, and a 3.9% higher rate of dizziness, beta-blockers have a 5.5% higher rate of dizziness, but a 5% lower rate of serious adverse events compared to placebo, MRAs have a 5.7% higher rate of male gynecomastia with spironolactone, and SGLT2 inhibitors have a 0.9% higher rate of genital infection 35

SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction

Guideline Recommendations

• The European Society of Cardiology recommends mineralocorticoid receptor antagonists, such as spironolactone or eplerenone, as part of quadruple therapy for heart failure with reduced ejection fraction, with a Class I recommendation 38
• The European Journal of Heart Failure suggests that SGLT2 inhibitors have unique advantages, including no blood pressure, heart rate, or potassium effects, and rapid benefit onset within weeks of initiation, making them suitable for immediate initiation 39

Medication Safety and Efficacy

• SGLT2 inhibitors are effective regardless of background therapy and are safe in moderate kidney dysfunction, with eGFR ≥30 ml/min/1.73 m² for empagliflozin and ≥20 ml/min/1.73 m² for dapagliflozin 39
• Vasodilators, such as hydralazine-isosorbide dinitrate, are not first-line therapy and are reserved for specific populations, according to the European Heart Journal 38

Treatment Outcomes

• The European Heart Journal states that calcium channel blockers are not part of guideline-directed medical therapy for heart failure with reduced ejection fraction and may actually worsen outcomes in this population 38

Heart Failure with Reduced Ejection Fraction (HFrEF) Management

Medication Selection and Optimization

• The American Heart Association recommends carvedilol as the preferred beta-blocker if refractory hypertension is present due to its combined α1-β1-β2-blocking properties 40
• For self-identified black patients with NYHA Class III-IV symptoms, the American College of Cardiology recommends adding hydralazine/isosorbide dinitrate to quadruple therapy 40
• The American Heart Association advises against using non-dihydropyridine calcium channel blockers, moxonidine, and alpha-adrenergic blockers in HFrEF patients, as they may increase the risk of worsening heart failure 40

Guideline‑Directed Quadruple Therapy for HFrEF and Related Recommendations

Evidence Supporting Quadruple Therapy

• In patients with heart‑failure with reduced ejection fraction (EF ≤ 40 %), initiating the four disease‑modifying drug classes—ARNI (or ACE‑I/ARB), beta‑blocker, mineralocorticoid‑receptor antagonist, and SGLT2 inhibitor—simultaneously at low doses and rapidly uptitrating to target doses reduces 2‑year mortality by ≈ 73 % compared with no disease‑modifying therapy. European Society of Cardiology (ESC) guideline; high‑quality evidence. 41
• Randomized controlled trials in HFrEF have consistently demonstrated robust mortality benefits for each of the four core drug classes, establishing them as the standard of care for systolic heart failure. ESC guideline; high‑quality evidence. 42

Pharmacologic Components

Renin‑Angiotensin‑Neprilysin Inhibitor (ARNI)

• Sacubitril/valsartan is preferred over ACE‑I or ARB, providing ≥ 20 % relative mortality reduction versus the 5‑16 % reduction seen with ACE‑I/ARB alone. ESC guideline; high‑quality evidence. 43

Beta‑Blockers

• The three beta‑blockers with proven mortality benefit—carvedilol, metoprolol succinate, bisoprolol—each confer ≥ 20 % relative mortality reduction and lower the incidence of sudden cardiac death in HFrEF. ESC guideline; high‑quality evidence. 43

Mineralocorticoid‑Receptor Antagonists (MRAs)

• Spironolactone or eplerenone provide ≥ 20 % relative mortality reduction in HFrEF. ESC guideline; high‑quality evidence. 43

SGLT2 Inhibitors

• Dapagliflozin or empagliflozin add significant mortality benefit without affecting blood pressure, heart rate, or potassium, and can be started immediately after hemodynamic stabilization. ESC guideline; high‑quality evidence (implicit from overall quadruple‑therapy data).

Ivabradine (Adjunct)

• Only 25 % of participants in the ivabradine trial were on optimal beta‑blocker doses, emphasizing that beta‑blocker uptitration to target doses must precede ivabradine for heart‑rate control. ESC guideline; moderate evidence. 44

Loop Diuretics (Symptom Relief)

• Loop diuretics are indicated for relief of volume‑overload symptoms in heart failure. ESC guideline; moderate evidence. 44

Initiation and Uptitration Strategy

• The STRONG‑HF trial showed that simultaneous initiation of the four core drug classes after hemodynamic stabilization leads to higher rates of medication use and faster achievement of target doses, addressing a treatment gap where < 25 % of eligible patients receive all four agents concurrently and only ≈ 1 % reach target dosing. ESC guideline; high‑quality evidence. 45

• Clinical assessment at every encounter should include vital signs, signs of congestion, and a three‑generation family history to identify possible inherited cardiomyopathies and guide therapy adjustments. ESC guideline; moderate evidence. 41

• Early post‑discharge follow‑up within 7–14 days after medication changes, with monitoring of volume status, blood pressure, renal function, and electrolytes, is recommended to ensure safe uptitration and detect adverse effects. ESC guideline; moderate evidence. 41

Special Populations & Adjunctive Therapies

• In HFpEF, strict systolic and diastolic blood‑pressure control is a Class I recommendation, reflecting strong guideline endorsement. ESC guideline; high‑quality evidence. 44

• Cardiac resynchronization therapy (CRT) is recommended only for patients with markedly prolonged QRS duration. ESC guideline; high‑quality evidence. 43

• Implantable cardioverter‑defibrillators (ICDs) are indicated for patients with ischemic cardiomyopathy and mild symptoms after they have received class I pharmacologic therapy for an appropriate duration. ESC guideline; high‑quality evidence. 43

Implementation & Patient Education

• Structured patient‑education programs (printed materials, mobile applications, video education) significantly improve adherence to guideline‑directed medical therapy and are associated with reductions in mortality and hospitalizations. ESC guideline; moderate evidence. 46

All bullet points are derived from cited references and reflect the strongest available evidence as indicated in the source material.

Evidence‑Based Pharmacologic Recommendations for HFrEF

Renin‑Angiotensin System Alternatives

• In patients who cannot tolerate or do not have access to an ARNI, guideline‑endorsed therapy recommends initiating an ACE inhibitor (e.g., lisinopril 10 mg daily, uptitrated to 40 mg daily) or an ARB (e.g., losartan 50 mg daily, uptitrated to 150 mg daily) to achieve comparable neuro‑hormonal blockade【47】.

Ivabradine Use

• Ivabradine (5 mg twice daily, target 7.5 mg twice daily) should be added only when a patient in sinus rhythm with NYHA class II‑III symptoms has a resting heart rate > 70 bpm despite maximally tolerated beta‑blocker therapy【47】.

Beta‑Blocker Selection and Dosing (American College of Cardiology)

• One of the three beta‑blockers with proven mortality benefit—carvedilol, metoprolol succinate, or bisoprolol—should be selected; each reduces all‑cause mortality by ≥ 20% in HFrEF【48】.
• Recommended initiation and target dosing:
  
  • Carvedilol – start 3.125 mg twice daily; target 25–50 mg twice daily.
  • Metoprolol succinate – start 12.5–25 mg daily; target 200 mg daily.
  • Bisoprolol – start 1.25 mg daily; target 10 mg daily【48】.

Considerations in Elderly Patients (≥ 65 years) (American College of Cardiology)

• All four cornerstone medication classes (ARNI/ACE‑I/ARB, beta‑blocker, MRA, SGLT2 inhibitor) remain indicated in older adults, but clinicians should perform more frequent monitoring of blood pressure, renal function, and electrolytes during dose uptitration to mitigate age‑related tolerability issues【48】.

Guideline‑Directed Medical Therapy Sequencing for HFrEF Patients with Low Blood Pressure

Initial Medication Prioritization

Blood‑Pressure Management Principles

Beta‑Blocker Initiation Criteria

RAAS Inhibition Strategy (ARNI/ACE‑I/ARB)

Adjunctive Measures for Low‑BP Patients

SGLT2‑Inhibitor Blood‑Pressure Profile

MRA Blood‑Pressure Profile

Guideline‑Directed Medical Therapy for HFrEF (LVEF ≤ 40%)

Quadruple‑Therapy Efficacy

• In adult patients with HFrEF (LVEF ≤ 40%), starting all four foundational drug classes simultaneously at low doses and uptitrating to target doses every 1–2 weeks reduces 2‑year mortality by ≈ 73 % versus no GDMT. ACC Class I, Level A 50

Renin‑Angiotensin System Inhibition

• The American College of Cardiology (ACC) recommends ARNI (sacubitril/valsartan) as the preferred agent because it yields ≥ 20 % relative mortality reduction, surpassing the 5‑16 % reduction seen with ACE‑I or ARB alone. ACC Class I, Level A 51
• When ARNI cannot be used, ACE inhibitors or ARBs remain Class 1, Level A recommendations. 51

Beta‑Blocker Therapy

• Only carvedilol, metoprolol succinate, and bisoprolol have demonstrated mortality benefit in HFrEF, each providing ≥ 20 % relative mortality reduction. ACC Class I, Level A 51
• Metoprolol succinate: start 12.5–25 mg daily; titrate to target 200 mg daily. 51
• Bisoprolol: start 1.25 mg daily; titrate to target 10 mg daily. 51
• Beta‑blockers should be introduced after volume status is optimized and IV diuretics, vasodilators, and inotropes have been stopped, using low initial doses in hemodynamically stable patients. ACC Class I, Level A 51

Mineralocorticoid Receptor Antagonists (MRAs)

• MRAs (spironolactone or eplerenone) confer ≥ 20 % relative mortality reduction and are Class 1, Level A therapies for HFrEF. [52][53]

SGLT2 Inhibitors

• Dapagliflozin or empagliflozin provide significant mortality benefit, constitute the fourth pillar of HFrEF therapy, and show clinical effect within weeks of initiation; no dose titration is required. ACC Class I, Level A [50][51]

Implementation Strategy (Simultaneous Initiation)

• The ACC endorses simultaneous initiation of ARNI (or ACE‑I/ARB), beta‑blocker, MRA, and SGLT2 inhibitor to address the current treatment gap where < 25 % of eligible patients receive all agents concurrently. 50
• Dose uptitration should occur every 1–2 weeks, with reassessment of blood pressure, renal function, and electrolytes 1–2 weeks after each increment. ACC Class I, Level A 50

Adjunctive Therapy – Ivabradine

• In patients in sinus rhythm with NYHA class II‑III symptoms and resting heart rate > 70 bpm despite maximally tolerated beta‑blocker, ivabradine may be added (start 5 mg twice daily; target 7.5 mg twice daily). ACC Class IIa, Level B 50

Follow‑Up and Monitoring

• Schedule early outpatient follow‑up within 7–14 days after any medication change to evaluate volume status, blood pressure, renal function, and electrolytes. ACC Class I, Level A [51][53]

Evidence‑Based Pharmacologic Therapy for HFrEF (LVEF ≤ 40%)

Renin‑Angiotensin System Inhibition

• ACE inhibitors are recommended for all patients with current or prior heart‑failure symptoms and reduced ejection fraction, unless contraindicated. 54
• When an angiotensin‑receptor‑neprilysin inhibitor (ARNI) cannot be used, an ACE inhibitor (e.g., enalapril low dose titrated to target) or an ARB (e.g., losartan titrated to target) should be prescribed. 54

Evidence‑Based Beta‑Blockers

• Only carvedilol, metoprolol succinate, and bisoprolol have demonstrated ≥20 % mortality reduction and a decrease in sudden cardiac death in HFrEF; these agents constitute the guideline‑recommended beta‑blockers. 55
• Beta‑blockers should be started after the patient is clinically stable, after volume optimization, and after discontinuation of intravenous diuretics, vasodilators, and inotropes. 54

Mineralocorticoid Receptor Antagonists (MRAs)

• Spironolactone or eplerenone each provide ≥20 % mortality reduction and lower the risk of sudden cardiac death in HFrEF. 55
• Initiation of spironolactone should begin at a low dose and be uptitrated toward a target dose (e.g., 50 mg daily). 54

Loop Diuretics for Volume Management

• Loop diuretics are essential for relieving congestion in HFrEF but do not confer a mortality benefit. 54
• Furosemide may be started at a low dose (e.g., 20–40 mg once or twice daily) and increased up to a maximum of 600 mg daily as needed. 54
• Torsemide may be started at 10–20 mg once daily with a maximum of 200 mg daily. 54
• Bumetanide may be started at 0.5–1.0 mg once or twice daily with a maximum of 10 mg daily. 54

Adjunctive Therapies for Specific Populations

• Hydralazine (25 mg three times daily) combined with isosorbide dinitrate (20 mg three times daily) should be added for self‑identified Black patients with NYHA class III–IV symptoms who remain symptomatic despite optimal quadruple therapy. 54

Clinical Pitfalls

• Accepting sub‑optimal medication doses without aggressive uptitration to target doses is discouraged; achieving target dosing improves outcomes. 55

Quadruple Guideline‑Directed Medical Therapy for HFrEF

Mortality Benefit of Full GDMT

• Initiating all four foundational drug classes (ARNI or ACE‑I/ARB, beta‑blocker, MRA, SGLT2‑inhibitor) within the first 2–4 weeks reduces 2‑year mortality by ≈ 73% compared with no disease‑modifying therapy. American College of Cardiology recommendation, high‑quality evidence. 56
• The same regimen lowers all‑cause mortality by 61% (hazard ratio 0.39; 95 % CI 0.32–0.49). American College of Cardiology, high‑quality evidence. 56
• Patients receive roughly 6 additional life‑years versus traditional dual‑therapy regimens and about 5.3 extra life‑years versus no disease‑modifying therapy. American College of Cardiology, high‑quality evidence. 56

ARNI (Sacubitril/Valsartan)

• Sacubitril/valsartan is strongly preferred over ACE‑I or ARB alone, delivering ≥ 20 % relative mortality reduction versus the 5–16 % reduction seen with ACE‑I/ARB monotherapy. American College of Cardiology, Class I, Level A. 57
• Recommended initiation dose: 49/51 mg twice daily; target dose: 97/103 mg twice daily. American College of Cardiology, dosing guidance. 58

ACE‑I/ARB Dosing (when ARNI not tolerated)

• Doses are based on robust trial data; recommended by the American College of Cardiology. 58

Evidence‑Based Beta‑Blockers

• Only carvedilol, metoprolol succinate (CR/XL), and bisoprolol have demonstrated ≥ 20 % mortality reduction in HFrEF; other beta‑blockers lack such evidence. American College of Cardiology, Class I. 58

• Dosing recommendations reflect trial‑derived regimens. American College of Cardiology. 58

Mineralocorticoid Receptor Antagonists (MRA)

• Spironolactone or eplerenone each provide ≥ 20 % mortality reduction and lower the risk of sudden cardiac death. American College of Cardiology, Class I. 58

• Dosing based on high‑quality trial data. American College of Cardiology. 58

SGLT2‑Inhibitors

• Dapagliflozin 10 mg QD or empagliflozin 10 mg QD (no titration) add significant mortality benefit, have minimal blood‑pressure effects, and produce clinical improvement within weeks. American College of Cardiology, Class I, Level A. 56

Loop Diuretics for Volume Management (symptom relief only)

• Loop diuretics are essential for decongestion but do not improve survival. American College of Cardiology, Class I for symptom control. 58

• Dosing derived from guideline‑supported trials. American College of Cardiology. 58

Monitoring After Dose Adjustments

• After each uptitration step (typically every 1–2 weeks), reassess blood pressure and heart rate. American College of Cardiology, monitoring recommendation. 58
• Overall monitoring schedule (including labs) should be performed at 1–2 weeks post‑increment. American College of Cardiology, Class I. 56

Cardiac Resynchronization Therapy (CRT) – Class I Indication

• Indicated for patients with:
• Supported by high‑quality evidence (multiple randomized trials). American College of Cardiology, Class I. [58][56]

Management of HFmrEF (LVEF 41–49 %)

• Continue all HFrEF‑directed therapies; discontinuation after EF improvement leads to deterioration. American College of Cardiology, Class IIa. 56
• SGLT2‑inhibitors receive a Class IIa recommendation based on subgroup analysis of EMPEROR‑Preserved. American College of Cardiology, Level B. 56

Elderly Patients (≥ 75 years)

• All four foundational drug classes remain indicated, but require more frequent monitoring of blood pressure, renal function, and electrolytes during uptitration. American College of Cardiology, Class I, Level A. 56